The Changes Of Serum Thrombospondin-1 And Plasminogen Activator Inhibitor-1 In Patients With Congenital Heart Disease Complicated With Pulmonary Hypertension

Objectives:To explore the levels and clinical significance of serum thrombospondin-1 (TSP-1)and plasminogen activator inhibitor-1 (PAI-1) in patients with congenital heart disease(CHD) complicated with pulmonary hypertension (PH)and to understand their relationship.Methods:85 patients with CHD were divided into 4 groups:pulmonary arterial pressure normal group(27cases, SPAP<30mmHg) (1mmHg=0.133 mmHg), mild PH group(22 cases,30 mmHg≤SPAP<40 mmHg), moderate PH group (17cases,40mmHg≤SPAP<70 mmHg) and severe PH group (19 cases, SPAP≥70 mmHg). The concentrations of serum TSP-1and PAI-1 were measured with enzyme-linked immunosorbent assay (ELISA).Rusults:1,Compared with control group, the concentrations of serum TSP-1 and PAI-1 increased remarkably in CHD groups. (p<0.01)2,The concentrations of serum TSP-1 and PAI-1 in each group of CHD were significantly difference. (p<0.01)3,There are positive relationships between the concentrations of TSP-1,PAI-1 and pulmonary arterial pressure of CHD. 4,There are no relationships between the concentrations of serum TSP-1,PAI-1 and the age of patients.ConclusionsThere are closely relations between the concentrations of serum TSP-1,PAI-1 and pulmonary arterial pressure in patients with CHD complicated with PH,and TSP-1,PAI-1 may be involved in the formation of pulmonary hypertension pathogenesis.